Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation Meeting Abstract


Authors: Abou-Alfa, G. K.; Macarulla, T.; Javle, M. M.; Kelley, R. K.; Lubner, S. J.; Adeva, J.; Cleary, J. M.; Catenacci, D. V. T.; Borad, M. J.; Bridgewater, J. A.; Harris, W. P.; Murphy, A. G.; Oh, D. Y.; Whisenant, J. R.; Chamberlain, C. X.; Jiang, L.; Gliser, C.; Pandya, S. S.; Valle, J. W.; Zhu, A. X.
Abstract Title: Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation
Meeting Title: 2021 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 39
Issue: 15 Suppl.
Meeting Dates: 2021 Jun 4-8
Meeting Location: Virtual
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2021-05-20
Language: English
ACCESSION: WOS:000708120602169
DOI: 10.1200/JCO.2021.39.15_suppl.4069
PROVIDER: wos
Notes: Meeting Abstract: 4069 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ghassan Abou-Alfa
    568 Abou-Alfa